. Author manuscript; available in PMC: 2021 Mar 1.

Published in final edited form as: Lancet Digit Health. 2020 Feb 13;2(3):e116–e128. doi: 10.1016/s2589-7500(20)30002-9

Table 2:

Treatment interaction with the QuRiS for DFS in patients with stage I and II lung cancer. High QuRiS score was associated with significant benefit from ACT, whereas low QuRiS in fact showed negative effect of ACT in training as well as both validation groups.

D₁			D₂ + D₃
QuRiS	HR (Surgery Alone Vs. Adj. Chemo)	P-Value	QuRiS	HR (Surgery Alone Vs. Adj. Chemo)	P-Value
Q_H	0.27 [0.07–0.95]	0.03	Q_H	0.07 [0.01–0.41]	<0.001
Q_I	1.32 [0.73–2.38]	0.4	Q_I	2.13 [0.99–4.54]	0.06
Q_L	2.15 [1.13–2.15]	0.02	Q_L	2.24 [0.95–5.30]	0.06